Intellia Therapeutics Inc (NTLA) 13.654 USD (+0.02%)

Intellia Therapeutics is a biotechnology company dedicated to developing therapies using CRISPR-Cas9 technology for genome editing.

biotechnology health

Price history of Intellia Therapeutics Inc

Performance & Momentum

6 Months 50.90 %

1 Year 37.55 %

3 Years 71.00 %

5 Years 83.19 %

Momentum

Unlock this indicator

Strategic Analysis

Intellia Therapeutics Inc • 2026

Intellia Therapeutics is a breakthrough biotechnology company focused on CRISPR genome editing, with an approach aimed at potentially curative treatments rather than chronic therapies. Its positioning is based on cutting-edge scientific expertise and the promise of creating value through highly differentiated therapies, but it still depends on clinical and regulatory validation.

Strengths

Highly differentiated technological positioning in genome editing, a segment with high scientific barriers
High value-creation potential if clinical candidates confirm their efficacy and safety
Exposure to a long-term theme that is attractive to investors specialized in innovative biotech

Weaknesses

Still limited commercial visibility, with heavy dependence on clinical trial results
Historically very volatile stock profile, reflecting strong sensitivity to execution risk and market sentiment

Momentum

Momentum appears favorable in the short and medium term, with a clear recent improvement contrasting with a still very weak long-term trend. Strategically, this reflects renewed investor interest in the CRISPR story, but the case remains speculative and requires durable clinical confirmation before it can be considered stabilized.

Analysis performed yesterday